Fibrolamellar Carcinoma
10
4
7
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
10%
1 trials in Phase 3/4
100%
2 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (10)
Agnostic Therapy in Rare Solid Tumors
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers
KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)
Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)